Lisa A. Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, outlines her views on some of the most important challenges for patients and clinicians in treating triple negative breast cancer (TNBC). Metastatic TNBC is the only major oncology subgroup that has not had an improvement in overall survival despite several developments in drug targets and combinatorial therapies due to TNBC tumors rapid adaptive programming. Dr Carey also touches on the practical challenges of bringing new drugs into clinical practice and disparities in the distribution of TNBC across different age groups and races and patient access to care. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.